Document is current

Any future updates will be listed below

Retraction Note: Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway

Crossref DOI link: https://doi.org/10.1007/s00280-026-04874-0

Published Online: 2026-03-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark